The Asilomar Conference of 1975 and the German Ethics Council offer guidance for a path towards prudent regulation in the face of unknown and significant risks.
AMA J Ethics. 2019;21(12):E1042-1048. doi:
10.1001/amajethics.2019.1042.
Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy.
AMA J Ethics. 2019;21(12):E1079-1088. doi:
10.1001/amajethics.2019.1079.
Wandy D. Hernandez-Gordon, CD(DONA), BDT(DONA), CLC, CCE(ACBE)
CHWs’ work underscores need for clinicians and organizations to respond to deeply entrenched, long-standing patterns of oppression in ways that draw upon lived experience.
AMA J Ethics. 2022;24(4):E333-339. doi:
10.1001/amajethics.2022.333.
Kristen N. Pallok and David A. Ansell’s “Should Clinicians Be Activists?” highlights how physician activists risk retaliation from “economically and socially” privileged physician leaders and organizational leadership who “have been trained to comply” with structural inequity.
AMA J Ethics. 2022;24(7):E694-696. doi:
10.1001/amajethics.2022.694.
Kyle B. Brothers, MD, PhD and Esther E. Knapp, MD, MBE
Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.
AMA J Ethics. 2018;20(9):E812-818. doi:
10.1001/amajethics.2018.812.